-

Autobahn Therapeutics to Present at the Stifel 2023 Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company leveraging its brain-targeting chemistry platform, validated biology and biomarker-driven strategies to develop restorative treatments for people affected by central nervous system (CNS) disorders, today announced that Kevin Finney, President and Chief Executive Officer, will present a company overview at the Stifel 2023 Healthcare Conference in New York on Wednesday, November 15, 2023, at 12:40 p.m. ET.

About Autobahn Therapeutics

Autobahn Therapeutics is a biotechnology company developing a portfolio of neuropsychiatric and neurodegenerative clinical candidates leveraging its brain-targeting chemistry platform. Autobahn aims to unlock new therapeutic opportunities through precision tuning of CNS exposure, pursuing validated clinical and biologic targets, and guiding development with biomarkers. The company’s pipeline is led by ABX-002, a thyroid hormone receptor beta (TRβ) agonist, being developed as a potential adjunctive treatment for people with MDD, including those who have had an inadequate response to their antidepressant. Autobahn Therapeutics is based in San Diego. For more information, visit www.autobahntx.com.

Contacts

Bill Slattery, Jr.
THRUST Strategic Communications
bill@thrustsc.com

Industry:

Autobahn Therapeutics

Release Versions
English

Contacts

Bill Slattery, Jr.
THRUST Strategic Communications
bill@thrustsc.com

More News From Autobahn Therapeutics

Autobahn Therapeutics Reports New Nonclinical Data Showing Elunetirom Rapidly Builds Synaptic Connections and Restores Cellular Energy Capacity in Neurons

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today reported new nonclinical data on the antidepressant mechanism of action for elunetirom, its lead investigational therapy in Phase 2 development for adjunctive treatment of bipolar depression and major depressive disorder (MDD). The data show that elunetirom rapidly increased the number of synaptic connections between neurons...

Autobahn Therapeutics Reports Positive Phase 2 Topline Data for Elunetirom in Bipolar Depression, Demonstrating Rapid, Robust, and Durable Antidepressant Effects

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced positive topline data from its Phase 2 AMPLIFY-BD trial evaluating elunetirom as an adjunctive treatment in patients with bipolar I or bipolar II depression, a disorder affecting approximately 7 million adults in the U.S. Elunetirom, a novel, oral, once daily, brain-penetrant CNS thyroid hormone receptor agonist, ac...

Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, Inc., a biotechnology company developing restorative treatments for people affected by neuropsychiatric disorders, today announced that management will participate in the following upcoming investor conferences in June. 2026 Jefferies Global Healthcare Conference Investor Meetings: Tuesday, June 2, 2026 Location: New York, NY 2026 UBS Virtual CNS Day Fireside Chat and Investor Meetings: Monday, June 15, 2026 Location: Virtual About Autobahn The...
Back to Newsroom